Quick Answer
Kalaris Therapeutics, Inc. reported Net Income Loss of -$43.44 million for the year ending 2025.
- Kalaris Therapeutics, Inc. showed an increase of +37.2% in Net Income Loss from 2024 to 2025.
- This data is from Kalaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$2.52 million | Q2 2019: -$5.30 million | Q3 2019: -$7.27 million | Q1 2020: -$9.34 million | Q2 2020: -$11.63 million | Q3 2020: -$23.61 million | Q1 2021: -$30.92 million | Q2 2021: -$37.59 million | Q3 2021: -$45.51 million | Q1 2022: -$43.86 million | Q2 2022: -$44.64 million | Q3 2022: -$42.07 million | Q1 2023: -$41.18 million | Q2 2023: -$45.27 million | Q3 2023: -$44.27 million | Q1 2024: -$3.41 million | Q2 2024: -$5.65 million | Q3 2024: -$38.08 million | Q1 2025: -$10.20 million | Q2 2025: -$11.35 million | Q3 2025: -$11.89 million.
- Over the full 7 years of available data (2019 to 2025), Kalaris Therapeutics, Inc.'s Net Income Loss has declined by 82.2%.
- Historical annual values: Fiscal year 2025: -$43.44 million | Fiscal year 2024: -$69.17 million | Fiscal year 2023: -$190.42 million | Fiscal year 2022: -$168.71 million | Fiscal year 2021: -$171.96 million | Fiscal year 2020: -$69.78 million | Fiscal year 2019: -$23.84 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: